SANSCO SERVICES - Annual Reports Library Services - www.sansco.net

ANNUAL REPORT 2000-2001

Consult your doctor.



TORRENT PHARMACEUTICALS LIMITED

Report Junction.com

Cover theme: Torrent's role does not start and end with medicines alone. Torrent, as part of its social responsibility, ran a much sought after public health awareness campaign. Parts of this campaign with visual supplements are reproduced in this annual report; for you adding *years* to your *life* and *life* to your *years* in consultation with your doctor.

SANGCO SERVICES - Annual Reports Library Services - www.sansco.net

Report Junction

CONTENTS

t	Corporate Information	3
t	Audit Committee	4
ŀ	Torrent Pharmaceuticals Ltd An Introduction	7
ŀ	Directors' Report	17
۲	Auditors' Report	29
٠	Audited Accounts including Schedules	32
ŀ	Statement pursuant to Section 212 of the Company's Act, 1956	52
ŀ	Cash Flow Statement	54
ŀ	Management's Discussion and Analysis	55
t	Accounts of Subsidiary Companies	63
r	General Shareholder Information	77





CORPORATE INFORMATION

DIRECTORS

Mr. Sudhir Mehta

Chairman

Mr. D. S. Shah

Prof. Erik Emil Anggard

Mr. Markand Bhatt (wef 19-Oct-2001) Mr. Kiran Karnik (wef 24-Jan-2001) Mr. S. H. Bhojani (wef 25-May-2001) Dr. Prasanna Chandra (wef 25-May-2001)

Mr. Samir Mehta

Managing Director

Dr. C. Dutt

Director (Research & Development)

AUDIT COMMITTEE

(formed on 24-Jan-2001)

Mr. Kiran Karnik

Mr. Markand Bhatt

Mr. D. S. Shah

Mr. S. H. Bhojani (wef 25-May-2001)

SECURITIES TRANSFER &

INVESTORS' GRIEVANCE

Mr. Markand Bhatt Mr. Samir Mehta

Chairman

Chairman

COMMITTEE

(Formed on 25-May-2001)

COMPANY SECRETARY

Mr. Parthiv Parikh

Dr. C. Dutt

AUDITORS

C. C. Chokshi & Co. Chartered Accountants

REGISTERED OFFICE

Torrent House,

Off Ashram Road, Ahmedabad - 380 009.

Fax

Telephone: 079-6585090 : 079-6582100

PLANT

Village Indrad,

Taluka Kadi, Dist. Mehsana Telephone: 02764-33671 Fax : 02764-33676

R & D FACILITY

Torrent Research Centre,

Near Kanoria Hospital, Village Bhat,

District Gandhinagar. Telephone: 079-3269124 : 079-3269135

WEB SITE

www.torrent-india.com

REGISTRARS &

MCS Limited,

TRANSFER AGENTS

101, Subh Shatdal Complex,

Opp. Bata Show Room, Ashram Road,

Ahmedabad - 380 009.

Torrent Pharmaceuticals Ltd.

AUDIT COMMITTEE

The Board constituted an Audit Committee in its meeting held on 24-Jan-2001. The current composition of the Committee is as under.

- * Mr. Kiran Karnik, Chairman
- Mr. Markand Bhatt
- Mr. D. S. Shah
- Mr. S. H. Bhojani (wef 25-May-2001)

All members of the Committee are non-executive directors with 2 members being independent directors (within the meaning of clause 49 of the listing agreement with the stock exchanges). The terms of reference of the Committee is reproduced below.

TERMS OF REFERENCE OF THE AUDIT COMMITTEE (Constitution, Functions, Role and Powers of the Audit Committee)

Constitution

- 1. The Audit Committee will consist of the following directors:
 - Mr. Kiran Karnik as Chairman
 - Mr. Markand Bhatt, Director
 - Mr. D. S. Shah, Director
 - Mr. S. H. Bhojani (wef 25-May-2001)
- 2. The Committe shall elect a Chairman from amongst themselves, who must be an "independent director." The Chairman shall, inter alia, attend the annual general meeting of the Company and provide clarifications on any matter relating to audit and answer shareholders queries.
- 3. The Secretary of the Company shall act as Secretary to the Committee.
- 4. The Committee shall call the following persons to attend and participate, but not vote, at the meetings of the Committee.
 - a. Statutory auditors of the Company.
 - b. Internal auditors of the Company, if any.
 - c. Director (Finance) or Head of Finance function.
 - In addition to the above, the Committee may call such executives and outside experts, if and when considered appropriate by the Committee.
- 5. The quorum for the Committee shall be higher of 1/3rd and 2 of its members, with a minimum of 2 "Independent directors."
- 6. The Audit Committee shall meet at least 3 times during a year as under:
 - a. Once in every 6 months.
 - b. Before finalization of annual accounts.
 - The Committee may decide to have more than 3 meetings.

Functions / Role / Powers

- 7. The following shall be the functions / role / powers of the Committee:
 - i. Reviewing internal controls and internal audit functions with the management / internal auditors.
 - ii. Oversight of the financial reporting process / disclosures and review of interim and annual financial statements before Board approval.
 - iii. Appointment / removal of statutory auditors and fixation of the fees for their audit and other services.
 - iv. Periodic discussions with the statutory auditors of the Company (whether before, during or after the audit) on internal control systems, nature and scope of audit, audit observations and areas of concern, if any.
 - v. Investigate any matter referred to it by the Board or within its terms of reference.



4

www.reportjunction.com


SANSCO SERVICES - Annual Reports Library Services - www.sansco.net

- vi. Review the outcome of internal investigations of material fraud, irregularity and failure of internal control system.
- vii. Review financial and risk management policies.
- viii. To look into substantial defaults, if any, in payments to depositors, debentureholders, creditors and shareholders.
- 8. In addition to the above, the Committee shall have such functions / role / powers, if any, as may be specified in the Companies Act, Listing Agreement with stock exchanges or any other applicable law.
- 9. The Committee shall have full access to information contained in the records of the Company and can seek information from any employee of the Company. The Committee may access external professional and legal advice, if so required in discharge of its functions.
- 10. The Committee may make recommendations to the Board on any matter within its purview, by passing appropriate resolutions in its meetings.

The Committee held its first meeting on 25-May-2001 and inter alia, reviewed and recommended to the Board the financial statements for the year 2000-01 and audited financial results as per clause 41 of the listing agreement. The Committee has no significant observation / comment on the financial statements or audited financial result under clause 41.

Report Junction.com

ionrent
Torrent Pharmaceuticals Ltd.





TORRENT PHARMACEUTICALS LIMITED - AN INTRODUCTION

BACKGROUND


Torrent Pharmaceuticals Ltd., founded in 1972 by Shri U. N. Mehta, operates with a philosophy of rapidly developing and marketing new formulations in niche therapeutic areas at affordable prices. With the launch of Trinicalm plus, an effective tranquillizer in CNS segment in the early seventies and Calcigard (Nifedipine) - a calcium channel blocker in the cardiovascular segment in 1985, Torrent has taken rapid strides in the last four decades to become a frontrunner in the areas of Cardiovascular and CNS and command a significant presence in Gastrointestinal and Anti-infective segments. Torrent was one of the first few Indian Pharma companies to make its foray into exports successfully, amply recognized in the "Export Excellence Award" bestowed by the Government of India. The formulations are largely developed in-house at its Research & Development Centre. Torrent, amongst the first few to realize the importance of research in India, created one of the finest infrastructures for both basic and applied research in Torrent Research Centre.

MARKETING


Domestic formulations (comprising branded pharmaceutical formulations sold in the domestic market) is the largest segment contributing 70% to the turnover in the year 2000-01 as compared to 55% in 1999-00. International operations, which mainly comprises selling branded formulations to less-regulated countries, contributed 8% to the turnover in 2000-01. The company also sources, manufactures and supplies insulin formulations to Novo Nordisk (India) Ltd.

Domestic Formulations

The marketing setup in domestic formulations, headed by a Executive Director, is divided into 3 divisions: Prima, Vista and Psycan, formed primarily based on product-doctor matrix. Each division is headed by two General Managers (GM-Marketing and GM-Sales) to provide adequate attention to both on the field and off the field operations. The divisions have separate field force for meeting doctors / chemists, marketing department for brand management and sales department for sales administration. In addition there is a supply chain function, medical services function and market research function to support these three divisions.



PRIMA - Contribution by Therapeutic Area 2000-01



PRIMA

Prima division offers mass products that cater to a vast base of prescribers, mainly in the therapeutic areas of gastrointestinals, pain management, CNS and anti-infective. This division is a primary contributor to the top line with about 48% of the total domestic formulations turnover of the Company.

Prima division's more than 500 employees in the field cover over 1,00,000 doctors comprising General Practitioners, Consultant Physicians, Surgeons, Pediatricians, ENT specialists, etc.

This division has the credit of launching many molecules for the first time in India.

